Phoenix Pharmacometric Productivity Challenge 2011

You may have seen this competition announced before, perhaps there are topics here on the forum that people would like to see solutions to… [size=3.5]Pharsight is pleased to announce the Phoenix ® Pharmacometric Productivity Challenge 2011. The Pharsight Phoenix Pharmacometric Productivity Challenge is a competition to recognize excellence in the application of pharmacometric software to critical problems in drug development. Pharsight is now accepting submissions from industry and academia. The Submission Deadline is January 31, 2011. The winning submission will be announced at the American Conference on Pharmacometrics (ACoP) to be held April 4-7, 2011 in San Diego, California. The lead entrant on the winning submission will be awarded registration and travel to AcoP. Please see Certara | Drug Development Solutions for additional information and/or to complete your Phoenix Challenge submission. Challenge entries will be evaluated based on innovative, leading-edge uses of pharmacometric toolkits on Phoenix, Pharsight’s desktop software platform for pharmacokinetic and pharmacodynamic (PK/PD) data analysis and modelling. Entries may include a pharmacometric workflow, a model development or fitting technique, a model validation method implemented using Phoenix, or novel use of other Phoenix-based software applications. The panel of judges for the Phoenix Pharmacometrics Challenge includes distinguished academic leaders from Pharsight’s Phoenix Centers of Excellence Program.[/size] [size=4]Additionally we are also pleased to offer a 2 day Pre-meeting Workshop, Saturday-Sunday, April 2-3 on Population Modelling with Phoenix NLME and Connect, it is now posted on the ACOP website: [/size]http://www.go-acop.org/2011/population-modeling-phoenix-nlme-and-connect

Only a couple of days left to submit your entry so if you have an interesting model or a neat workflow e.g. for RSABE then get it submitted! I’ll also ask here what do people want to see more of in this forum? Simon.